Last updated 2026-08-12
- Acquired by Sevion Therapeutics, Inc., Dec 2017
- Went public on Nasdaq Capital Market (ELOX), Jun 2026
- Raised $66M Follow-on PO, Jun 2026
Total raised
$175.0M
Last: Public Offering 2026-06
Stage
Public
Founded
2013
Headcount
30
HQ
Arlington, United States
Sector
Drug Discovery
About
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The company's lead product candidate, ELX-02, is in Phase III clinical trials for the treatment of cystic fibrosis. Eloxx also has preclinical candidates for autosomal dominant polycystic kidney disease (ADPKD) and Usher syndrome. The company's major products include platform technologies such as Turbo ZM and Ribosome Modulating Agents (RMAs), specifically Eukaryotic Ribosomal Selective Glycosides (ERSGs). Eloxx Pharmaceuticals was founded in 2013 by Dr. Silvia Noiman and Dr. Shmuel Tuvia. While originally founded in Israel with R&D operations in Rehovot, Israel, the company's headquarters are now in Arlington, Massachusetts, US.
Funding history · 13 rounds · $175.0M total
2026-06
Follow-on PO
$66.0M
2024-07
Debt Financing
$3.5M
2023-09
PIPE
Undisclosed
2023-08
Follow-on PO
$4.2M
2023-05
Follow-on PO
$6.5M
2022-05
Follow-on PO
$13.0M
2021-10
Debt Financing
$12.5M
2021-05
Follow-on PO
$50.0M
2021-01
Grant
$2.0M
2018-03
Follow-on PO
Undisclosed
2017-06
C Round
$8.0M
★ LSP★ PontifaxKIPQuarkothersCatalystDSC FundsPhil FrostGF CapitalOPKO HealthPontifax VCGF SecuritiesPhillip FrostDSC InvestmentLSP BioVenturesDSC InvestmentsSevion TherapeuticsQuark PharmaceuticalsSamsung Catalyst FundKorea Investment Partnersadditional private investorsKorean Investment Partners (KIP)Catalyst CEL - Israeli Chinese fund
2015-04
B Round
$900K
2013-10
A Round
$8.5M
★ Pontifax
Headcount over time
From 25 (2018-08) to 7 (2026-08) · -18 (-72%) · 43 points · source: Finder history + radar grounding
Q&A
- What is Eloxx Pharmaceuticals' primary focus?
- Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel RNA-modulating drug candidates for rare and ultra-rare premature stop codon diseases.
- When did Eloxx Pharmaceuticals go public?
- Eloxx Pharmaceuticals went public on NASDAQ in April 2018.
- What is the status of Eloxx Pharmaceuticals' lead product candidate, ELX-02?
- ELX-02, Eloxx Pharmaceuticals' lead product candidate, is in Phase III clinical trials for the treatment of cystic fibrosis.
- What was the most recent funding event for Eloxx Pharmaceuticals?
- In July 2024, Eloxx Pharmaceuticals secured a Debt Financing round totaling $3,463,000.
- What was the amount of Eloxx Pharmaceuticals' Public Offering in May 2023?
- In May 2023, Eloxx Pharmaceuticals completed a Public Offering that raised $6,500,000.
- What was the amount of Eloxx Pharmaceuticals' Public Offering in August 2023?
- In August 2023, Eloxx Pharmaceuticals completed a Public Offering that raised $4,200,000.
- What was the amount of Eloxx Pharmaceuticals' PIPE round in September 2023?
- In September 2023, Eloxx Pharmaceuticals completed a PIPE round that raised $2,000,000.
- What is the current employee count for Eloxx Pharmaceuticals?
- Eloxx Pharmaceuticals has 11-50 employees.
- What was the most recent Public Offering amount for Eloxx Pharmaceuticals?
- In June 2026, Eloxx Pharmaceuticals completed a Public Offering that raised $65,969,750.
Team · 14
Dr. Silvia Noiman
Founder · Board Member
Sumit Aggarwal
Chief Executive Officer
Teji Singh
Head of Clinical Development
Robert Ward
CEO
Gregory Weaver
CFO
Miguel de los Rios
VP, R&D
Dr. Pedro Huertas
Chief Medical Officer
Brett Hagen
Controller
Barbara Ryan
IR
Dr. Zafrira Avnur
Independent Director
Martijn Kleijwegt
Independent Director
Ran Nussbaum
Board Member
Jasbir Seehra
Board Member
Gadi Veinrib
Independent Director
Sectors & technology
Primary sector
Drug Discovery
Technologies
Target customers
Business model
Biopharmaceutical Development
Highlights
1 Patents
Tags
rare-diseasesdrug-discoverybiopharmaceuticalbiotechnologytherapeuticspharmaceuticalspharma-companiespatientsgenetic-disorders
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | eloxxpharma.com |
|---|---|
| linkedin.com/company/18504171 | |
| Wikidata | wikidata.org/wiki/Q106411647 |
Identifiers & details
| Legal name | Eloxx Pharmaceuticals, Inc. |
|---|---|
| Founded | 2013 |
| Employees (exact) | 30 |
| Offices | Watertown |
| Market cap | $314 |
| Status reason | Public on NASDAQ on Apr, 2018 |
| Wikidata QID | Q106411647 |
Acquisitions & public offerings
Acquired by Sevion Therapeutics, Inc. 2017-12
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Public Offering | 2026-06 | Nasdaq Capital Market | ELOX | $66.0M |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | eloxxpharma.com |
|---|
Wikidata
| QID | Q106411647 |
|---|
Certificate / subdomain footprint
| Subdomains | 11 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514970706 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2013-09-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | דרך הנפת הדגל 7 נס ציונה |